
Astral Gears Up for Q3 Reveal on 5th February; Check Key Expectations Here
Updated: 4 Feb 2026 • 1:23 pm
Posted by:

Click and Sign Up to Get Live Updates on Q3 Results
Astral’s Q3 results FY26 are scheduled to be announced on 5th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Astral Q3 Results 2026 Preview
- Astral’s revenue is expected to be in the range of ₹1,397.00 crore, a 1.94% YoY increase.
- Profit After Tax, or PAT, is projected to rise 3.73% YoY.
- Net profit is ₹114.10 crore, up 3.73% YoY
- EBITDA to rise 4.13%
Astral Share Performance
- Over the past six months, Astral’s share price has risen by 4.31% to ₹61.50.
- Moreover, over the past year, the stock has decreased by 1.02%.
- Despite this weak short-term performance, Astral’s stock has delivered a financially sound 32.26% return over the past 5 years.
- As of 4th February 2026, the stock traded at ₹1,489.50 per share.
Key Factors to Watch for Astral Q3 Results FY26
- Revenue Growth & Segment Performance: The emphasis will be on revenue growth and volume momentum in the pipes, fittings, and adhesives business. This will help assess whether the demand is strong in the major end markets.
- Margins & Profitability: EBITDA and net profit margins will help assess Astral’s cost competitiveness and pricing power. The PVC and chemical price trends will be critical in determining the margins.
- Raw Material Cost Trends: The PVC and chemical price trends will be closely watched in the quarter. The company’s ability to recover prices will have a bearing on profitability.
- Capacity Expansion & Capex: Information on capacity expansion and utilisation will provide an indication of future growth opportunities. Improved utilisation can help drive operating leverage.
- Management Outlook & Guidance: The company’s outlook on demand, prices, and costs will be important for market guidance. Forward-looking guidance can help shape market reaction post the result.
Final Thoughts
Astral will announce its Q3 FY26 results on 5th February 2026. Analysts expect 1.94% revenue growth, a 3.73% rise in PAT, and a 4.13% fall in EBITDA. Astral Q3 FY26: Watch revenue and volumes, margins, raw material costs, capacity expansion, and management guidance for growth outlook.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Archean Chemical Industries Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Advent Hotels International Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Andhra Paper Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Apollo Tyres Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Aptus Value Housing Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Associated Alcohols & Breweries Gears Up for Q3 Reveal on 4th February; Check Key Expectations Here
Recent Articles

LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
15 May 2026

Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
15 May 2026

Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
15 May 2026

Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
15 May 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV
Popular this week
LT Foods Q4 FY26 Results: PAT of Rs 135.67 crore Basmati Rice and Food Products
Muthoot Finance Q4 FY26 Results: PAT of Rs 10,607 (FY26 consolidated annual) crore (up 98% Yo Gold Loan NBFC
Alivus Life Sciences Q4 FY26 Results: Announced May 14 2026 Pharma API and CDMO – Formerly Glenmark Life Sciences
Chalet Hotels Q4 FY26 Results: Announced May 14 2026 Luxury and Business Hotels
Tata Motors Passenger Vehicles Q4 FY26 Results: PAT of Rs 2,406 (standalone Tata Motors) crore (up 69.55% Yo Passenger Vehicles and EV

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas





